<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The accumulation of risk factors for central <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:mp ids='MP_0006134'>artery occlusion</z:mp> can be seen in a single person and might be explained by the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>CASE REPORT: We presented the case of a 52-year-old man with no light perception in his right eye </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:hpo ids='HP_0000572'>visual loss</z:hpo> was monocular and painless, fundoscopy showed central <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:mp ids='MP_0006134'>artery occlusion</z:mp> and the laboratory investigation showed the <z:hpo ids='HP_0003565'>raised erythrocyte sedimentation rate</z:hpo> of 105 mm/h and the raised C-reactive protein of 22 mg/l </plain></SENT>
<SENT sid="3" pm="."><plain>Specific laboratory investigations and <z:chebi fb="0" ids="31624">fluorescein</z:chebi> angiography excluded the presence of <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, <z:e sem="disease" ids="C0262428" disease_type="Disease or Syndrome" abbrv="">collagen vascular diseases</z:e>, <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: The patient met <z:hpo ids='HP_0000001'>all</z:hpo> the five of the National Cholesterol Education Program (NCEP) criteria for the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>: <z:hpo ids='HP_0000822'>hypertension</z:hpo>, abnormal <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, abnormal <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Measurement of C-reactive protein is useful for the assessment of therapeutic systemic effect on any abnormality in the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Individual therapy for <z:hpo ids='HP_0000001'>all</z:hpo> risk factors in the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is necessary to prevent complications such as cardiovascular, <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>